Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 5/20 | 0.55 |
| ▸ | SLC1A2 | P43004 | 5/20 | 0.55 |
| ▸ | SLC1A1 | P43005 | 5/20 | 0.55 |
| ▸ | KMO | O15229 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 3/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.38 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Serine SCHEMBL561331 | 0.80 | ALPI (0.50) | SLC1A3SLC1A2SLC1A1KIF11 | |
| Serine SCHEMBL7658418 | 0.80 | ALPI (0.50) | SLC1A3SLC1A2SLC1A1KIF11 | |
| (D)-Serine SCHEMBL6794292 | 0.80 | ALPI (0.50) | SLC1A3SLC1A2SLC1A1KIF11 | |
| Chlorobenzene SCHEMBL29194922 | 0.74 | KIF11 (0.55) | SLC1A3SLC1A2SLC1A1KMOCYP1A2 | |
| Chlorobenzene SCHEMBL29194921 | 0.74 | KIF11 (0.55) | SLC1A3SLC1A2SLC1A1KMOCYP1A2 | |
| Acetamide SCHEMBL27382435 | 0.74 | NOTUM (0.45) | SLC1A3SLC1A2SLC1A1HSP90AA1 | |
| SCHEMBL6904514 | 0.73 | HTR2A (0.50) | CYP3A4HSP90AA1 | |
| Bromide SCHEMBL189011 | 0.71 | — | — | |
| Ammonia Solution, Strong SCHEMBL1325642 | 0.71 | — | — | |
| Serine SCHEMBL11022238 | 0.69 | SLC1A5 (0.53) | SLC1A3SLC1A2SLC1A1KMOKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114906-B1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2014-08-06 | — | — | EP | disclosed |
| US-8604061-B2 | 2-aminooxazolines as TAAR1 ligands | HOFFMANN-LA ROCHE INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20120196903-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | GALLEY GUIDO (DE) | 2012-08-02 | — | — | US | disclosed |
| US-20100120864-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | GALLEY GUIDO | 2010-05-13 | — | — | US | disclosed |
| EP-2114906-A1 | NOVEL 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS | F. Hoffmann-Roche AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-20080261920-A1 | 2-Aminooxazolines as TAAR1 ligands | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-23 | — | — | US | disclosed |
| WO-2008092785-A1 | NOVEL 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120864-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | TAAR1, TAAR5, NPY2R | SLC1A3 169/4885SLC1A2 17/4885SLC1A1 73/4885 |
| US-20120196903-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | TAAR1, TAAR5, NPY2R | SLC1A3 157/4885SLC1A2 13/4885SLC1A1 74/4885 |
| US-20080261920-A1 | 2-Aminooxazolines as TAAR1 ligands | TAAR1, TAAR5, NPY2R | SLC1A3 169/4885SLC1A2 17/4885SLC1A1 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.